Member Info for AquaeSulis01

I dare say he would martini depending on the number of emails sent at anyone time, just made sense to liaise through lemmings as I am a subscriber and then share the response with the many who know doubt have similar questions.

Loads, as I stated, the question was mine and the response came via lemmings who are a honest broker and have no motive to adulterate t h e response from SOH. I have reproduced the words regarding rapid route to market, only the smiley then all good was a lemmings add on to me

I wanted to clarify whether structural as well as taste had passed independent scrutiny so posed the following question to SOH through the good offices of the much maligned Lemmings;

Q"I note the main progress update for Sweetbiotix since the 19th July 2023 Reach RNS appears to be that the US Partner Expert panel testing of the scale manufactured product has shown comparable taste and texture when compared to the laboratory product, so does this mean that both the Liquid and freeze-dried products have also passed independent structural analysis and hence are covered by the original patent and GRAS which I believe despite the US partner carrying out minor Customer Trials, was a concern for SOH who would not allow it to go out labelled as Sweetbiotix?"

A "'Everything is completed, we have a range of sweetbiotix products and believe we have a rapid route to regulatory compliance. Smiley, then, all looking good."

Summing up the position with Sweetbiotix from the history of RNS updates and Interviews with SOH;

The US Partner was aiming to produce sweetbiotix at a cost within 10% of the price of sugar which was why the optimisation process on scale-up to remove waste took so long.

Tate and Lyle were one of the named partners who have had access to sweetbiotix for a number of years so potentially a speedy route to market for granulated sweetbiotix, even a restricted early use of sweetbiotix in bags direct to consumers with the right marketing would quickly see it replace sugar for tea and coffee sweeteners leading to a seven figure royalty return per annum.

SOH appears to have confirmed both structural and taste testing have passed independent panel scrutiny and hence will qualify as GRAS in the USA

Surely the market should be more excited about this than it currently is?

Bigpunt, I am probably being thick now but doesn't this answer your question "For FY24, Dermatonics reported revenues of £1.86 million (2023: £1.82m) assisted by the increased sale of products into the NHS and podiatry clinics, at higher price points negotiated in February 2023, as well as growth in key distributor relationships outside of the UK."?

On a separate note, I know a lot has been made about the Cavendish projections for Dermatonic EBITDA which have led to questions over whether the acquisition is truly accretive when loan costs are factored in, but surely we have not just bought additional products but acquired all the Company’s assets which include its people and market channels, so we should be looking at the projections for Skinbiotherapeutics at the Group level to determine whether the Dermatonics contribution is accretive or not? For instance, Dermatonics products are stocked and sold through Boots offering an opportunity to add Axisbiotix-ps to the range. Having someone who knows Boots and the way it works before approaching the buyers, will give Boots the confidence that Skinbiotherapeutics has the knowledge and experience within the company to trade successfully with them, consequently, there is a strong probability that we will get a RNS in the not too distant future announcing a deal leading to a material impact on the revenues received for Axisbiotix-ps and hence ought to be factored in to any accretion projections. The selling to Boots as a retailer advice seems to indicate that Skin has potentially ticked the important boxes.

https://businessadvice.co.uk/supply-chain/sourcing-suppliers/selling-to-boots-a-retailer-hoping-to-find-a-nugget-from-independent-suppliers/

It has already been explained Bigpunt during the Investor Meets presentation, the once off write-offs resulted from the cessation of an agreement with a partner to sell the Natural Range Heel Balm containing Manuka honey in the USA which artificially inflated revenues for the 23 comparative figures

Noting from today’s RNS that “For FY24, Dermatonics reported revenues of £1.86 million (2023: £1.82m) assisted by the increased sale of products into the NHS and podiatry clinics, at higher price points negotiated in February 2023, as well as growth in key distributor relationships outside of the UK.” the results for the New Cross Hospital trial for the Heel Pressure Ulcer trial could well trigger a material update in revenue projections. A few Govt facts;

https://www.gov.uk/government/publications/pressure-ulcers-applying-all-our-health/pressure-ulcers-applying-all-our-health

“Facts about pressure ulcers

Older people are the most likely group to have pressure ulcers. This is especially true for those older than 70, up to a third of whom will have had surgery for a hip fracture. Age alone is not a risk factor. Instead, it is the problems common in older people that are associated with pressure ulceration. For example hip fractures, faecal and urinary incontinence, smoking, dry skin, chronic systemic conditions, and terminal illness.

Those with spinal injuries form another distinct group. In this group the prevalence is 20% to 30%, 1 to 5 years after injury.

Pressure ulcers in older patients are associated with a fivefold increase in mortality. In addition, in-hospital mortality in this group is 25% to 33% (Grey, 2006).

Pressure ulcers can result in longer lengths of stay in hospitals. One study found that adult patients who develop pressure ulcers had an extended stay of over 4 days (Graves, 2005). Another study found patients over 75 years of age, who develop a pressure ulcer in hospital, had a 10 day longer stay (Theisen, 2012).

Treating pressure ulcers costs the NHS more than £1.4 million every day (Guest et al. 2017).”

Also worth noting that whilst there are a reported 1257 hospitals in the UK, they are managed by just 219 trusts. For instance, Ipswich Hospital falls under East Suffolk and North Essex Trust which also manages Colchester Hospital, whilst New Cross Hospital falls under the Royal Wolverhampton NHS Trust which also runs West Park Hospital and Cannock Chase Hospital and runs R&D Projects across the whole of the West Midlands, with links across England through ithe National Co-ordinating Centre so any successful trial of Once Hell Balm could see a fairly rapid roll out.

https://www.royalwolverhampton.nhs.uk/about-us/research-and-development.html

Yes Toyin, there is also the launch of the Natural Range Heel Balm containing Manuka honey to be launched on USA Amazon which sold 50000 units through the former partner. Also, noting Stuart mentioned he had taken a call from one of the Companies looking to partner in the Medi pillar following the acquisition, makes you wonder whether a Smith & Nephew or Croda with their American contacts would consider promoting a launch of the professional Once Heel Balm containing Urea to the US hospitals whilst they carry out clinical trials on skinbiotix as an active ingredient for wound care.

This involves the microbiome modulators

First of all a link to the spectacular clinical results for Dermatonic’s Once Heel Balm

https://diabetesonthenet.com/wp-content/uploads/pdf/dotnc92b099e511705f109f5e6b10485e0d2.pdf

Now putting it all together with the Investor Meets presentation where we were told that Ipswich Hospital reduced Diabetic Foot Ulcers using Once Heel Balm by 2/3rds yet it has only been rolled out to 10 NHS Hospitals in total leaving a huge potential market to exploit of 1247

https://www.sanctuarypersonnel.com/blog/2020/10/how-many-nhs-hospitals-are-there-in-the-uk?source=google.com

In addition, news is imminent from the New Cross Hospital on the use of Once Heel Balm on Heel Pressure Ulcers associated with the elderly which if successful will further expand the market for this product.

I have previously advocated that the 5 Pillars should be renamed to reflect the market segment the products are targeted at rather than the first two being brand specific; the recent acquisition reinforces that view. So instead of Skinbiotix, Axisbiotix, Medibiotix, Cleanbiotix and Pharmabiotix we would have Cosmetic, Food Supplements, Medical, Cleaning, and Pharmaceutical. We formerly had Skinbiotix and Axisbiotix psoriasis and Acne listed as early commercial in the first two pillars respectively with the other pillars blank, but the slide reflecting this in the presentation needs updating. Dermatonics have two product groups; The Natural Care range which reside in the Cosmetics Pillar, and the Professional Range which reside in both the Medical and Pharmaceutical Pillar i.e. “Medibiotix” and “Pharmabiotix” are now commercial too

https://www.dermatonics.co.uk/

A time when NHS podiatry workforce numbers are challenged to meet increasing demand, Dermatonics could prove to be an important tool in the prevention of ulceration. The potential human and financial benefits for a low-cost prevention strategy by using Dermatonics on neuropathic callus are significant with savings to the NHS estimated to be as much as £120m (Lunn, 2018) and should be explored by commissioners, prescribers and clinicians across all areas of the foot care pathway" extract from the clinical trial for the heel balm which I meant to include with the previous post

The heel balm really is quite impressive, can see why it may well help clinch a deal for the lysate in the medibiotix pillar where Stuart had spoken in particular about the foot ulcer target market.

Yes Sry Toyin just fed up with so many speculative sales indicators seized on over the years with axis that have come to nothing. Need something concrete to celebrate. Thought we would get the Dermatonics figures posted this week rather than something drip fed to Cavendish for their paid for followers

Another 1 has flown off the shelves Toyin

McDonald’s

Surely Golden Arches isn’t the spot for a healthy bite on the move? Not if you order burgers, fries and sugar-laden condiments. “But the grilled chicken salad meal is better for you than any burger,” Kerrigan says. “It comes with water and a bag of carrots to munch on, and in terms of calories, saturated fat and salt, beats burgers hands down.” For breakfast, go for plain porridge, without added sugar, jam or golden syrup.

Breakfast

Porridge with organic semi-skimmed milk, and wholegrain jumbo oats

Porridge with organic semi-skimmed milk, and wholegrain jumbo oats

Calories: 154

Nutrition: Low in saturated fat , no salt or sugar added, a good amount of protein.

Taste: Hot, creamy and surprisingly delicious. (4.5/5)

Satiety: The small serving didn’t fill me up but it did tide me over for an hour or so. (3.5/5)

Total score: 4/5

Adding Slimbiome could result in a 5/5 score

https://www.telegraph.co.uk/health-fitness/diet/nutrition/healthiest-meal-option-in-fast-food-restaurants/

Thanks mol, good finds

Dermatonics heel balm sold over 700 last month

https://www.amazon.co.uk/Dermatonics-Suitable-Diabetics-Hydrates-Moisture/dp/B09MR5PF5N/ref=sr_1_7?crid=2RKCX4C5CHOM6&keywords=heel+balm&qid=1706805207&sprefix=heel+balm%2Caps%2C228&sr=8-7

Toyin, I'll start to get excited when I see 300 sold in the last month which is also the sort of stat Amazon likes to publish

If Amazon fail to deliver next day when promised then they will merely refund the delivery charge

The introduction of The Procurement Act will make it easier for Small Enterprises to do business with the NHS and is very timely for Skin

https://www.gov.uk/government/publications/benefits-for-prospective-suppliers-to-the-public-sector/benefits-for-prospective-suppliers-to-the-public-sector

Guess it was sheer coincidence that the Opti sp increased after a period of stagnation on no news other than the value of one of its assets, Skin, had decreased 20% then.

Technically this type of fund raising is classed as a death spiral Clio although the final para is appropriate for the purpose the Company is using it for. https://www.investopedia.com/terms/d/deathspiral.asp